Pharma

Is AMD Drug-Treatment Landscape Shifting?

Is AMD Drug-Treatment Landscape Shifting?

By Rich Kirkner | June 28, 2017

When Novartis last week announced positive outcomes from two Phase III trials for new age-related macular degeneration (AMD) drug brolucizumab (RTH258), it seemed the other…

Read More
Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps

Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps

By Rich Kirkner | May 31, 2017

With the recent report of successful top-line Phase III results of its fixed-dose glaucoma candidate Roclatan, Aerie Pharmaceuticals Inc. has seen its stock price soar…

Read More
Dry Eye Newbie Xiidra Grabs Large Market Share

Dry Eye Newbie Xiidra Grabs Large Market Share

By Michelle Dalton | May 19, 2017

During the run-up to the launch of Shire’s dry eye drug Xiidra (lifitegrast), it seemed as though everyone was wondering what kind of threat –…

Read More
With Positive Phase I/IIa, Opthea Looks to Next Step

With Positive Phase I/IIa, Opthea Looks to Next Step

By Rich Kirkner | April 20, 2017

Coming off word that the Phase I/IIa clinical trial of its novel anti-VEGF candidate for treatment of age-related macular degeneration exceeded expectations, along with positive…

Read More
Gottlieb Brings VC Toolkit to FDA

Gottlieb Brings VC Toolkit to FDA

By Rich Kirkner | April 12, 2017

Soon-to-be FDA commissioner, Scott Gottlieb, MD, is well positioned to understand where the medtech and biotech communities are coming from. He’s been a partner at…

Read More
AXIM Rolls Medical Marijuana Ball in Ophthalmology

AXIM Rolls Medical Marijuana Ball in Ophthalmology

By Rich Kirkner | April 5, 2017

Medical marijuana has quickly gained acceptance as a viable treatment for a variety of health conditions, such as the side effects of chemotherapy, the neurodegenerative…

Read More
How Regeneron Aims to Stay on Message with VR/AR App

How Regeneron Aims to Stay on Message With VR/AR APP

By Steve Lenier | March 29, 2017

Virtual reality has been used to train surgeons, to evaluate balance control and associated fall risk in glaucoma patients, and, more recently, to create simulations…

Read More
Clearside Goes All In for CLS-TA

Clearside Goes All in for CLS-TA

By Rich Kirkner | March 15, 2017

Late last year, when developers of agents that combined anti-platelet derived growth factor with an anti-vascular endothelial growth factor (anti-PDGF/anti-VEGF) to treat wet age-related macular…

Read More

Is Trump Opening New Front in War on Drug Prices?

By Rich Kirkner | January 18, 2017

Pharma executives were beaming as their stock prices soared in the days after Donald Trump’s poll-defying victory, and their sentiments rose even higher with the…

Read More
After Phase III Disappoints, Inotek Looks to Fixed-Dose Combination - Eye On Innovation - OIS

After Phase III Disappoints, Inotek Looks to Fixed-Dose Combination

By Rich Kirkner | January 11, 2017

As Inotek Pharmaceuticals sifts through the disappointing Phase III top-line results for its lead clinical candidate trabodenoson and the 66% stock price slide that followed,…

Read More
What’s Next for Sun Ophthalmics after BromSite Launch? - OIS - Eye On Innovation Article - Healthegy

What’s Next for Sun Ophthalmics After BromSite Launch?

By Rich Kirkner | December 7, 2016

With the launch last week of BromSite to treat inflammation and prevent pain after cataract surgery, India-based Sun Pharma has taken a significant step in…

Read More
Following Xiidra Approval

Following Xiidra Approval, a Look Back at OIS@ASCRS Dry Eye Breakout Session

By Michael Lachman | August 25, 2016

The FDA approval last week of Xiidra (lifitegrast ophthalmic solution) from Shire plc represents a major milestone for the dry eye market. Restasis, which was…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.